Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

tivantinib

Daiichi Sankyo logo

Daiichi’s new anticoagulant recommended by NICE

Lixiana nears NHS funding approval for certain patients with atrial fibrillation

AstraZeneca AZ

Iressa set for US market return after FDA approval

AstraZeneca'slung cancer drug wins green light for EGFR tumours

Eli Lilly HQ

Lilly closes on US approval of lung cancer drug necitumumab

Indication for NSCLC looking likely after informal panel poll

Daiichi Sankyo logo

Daiichi Sankyo gets EU OK for Lixiana anticoagulant

Japanese firm’s latest product faces tough competition from a fierce NOAC market

ASCO 2015: What you missed in Chicago

Blue Latitude sent two of our consultants to Chicago to attend ASCO 2015, a key annual meeting for oncology specialists that brings over 30,000 delegates together to talk about innovations...

Blue Latitude Health

- PMLiVE

Amgen and Merck to expand cancer collaboration

Firms to test Keytruda in combination for cancers inside the head and neck

- PMLiVE

Rise in cancer therapy costs ‘unsustainable’ says oncologist

Leonard Saltz made the claims in his keynote presentation at ASCO

- PMLiVE

FDA approves Pfizer’s new cancer pill

Drug was previously approved as an organ rejection treatment

- PMLiVE

Afinitor set for filing this year in neuroendocrine cancer

Novartis drug is already approved for breast and renal cancers

- PMLiVE

Ipsen acquires OctreoPharm to boost its oncology presence

Will aid the development of its approach to neuroendrocrine tumours

- PMLiVE

Novartis still hungry after absorbing GSK oncology

CEO says firm is looking to strengthen pipelines in its three businesses

Roche Basel Switzerland

Roche adds kidney cancer to anti-PD-L1 programme

Inhibitor already indicated for lung, bladder and breast cancer

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links